Reuters logo
BRIEF-Depomed falls after FDA advisory committee rejects menopause drug
March 4, 2013 / 6:51 PM / in 5 years

BRIEF-Depomed falls after FDA advisory committee rejects menopause drug

NEW YORK, March 4 (Reuters) - Depomed Inc : * Resumes trading down 15.8 percent to $5.50 after FDA advisory committee rejects menopause drug

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below